Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma.
The emergence of effective systemic chemotherapy, along with the parallel development of new targeted cell signal inhibitors for pancreatic cancer treatment, has provided impetus for a re-examination of the appropriate use of chemotherapy and radiation therapy in this malignancy. In addition to exciting developments in the treatment of locally advanced and metastatic disease, new data have emerged regarding the efficacy of adjuvant and neoadjuvant therapy when combined with traditional surgical approaches such as a Whipple procedure. This review summarizes the sentinel clinical trials and discoveries that have influenced the development and deployment of scientifically based multidisciplinary care for today's patients, with a particular focus on modern radiation and chemotherapy.
Marsh
Robert de W
Rde W
University of Florida Shands Cancer Center, Gainesville, FL 32610, USA. marshrd@medicine.ufl.edu
George
Thomas
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000592:standards / Q000627:therapeutic use; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D010183:Pancreatic Ducts; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis